Requests for Applications
Milton Safenowitz Postdoctoral Fellowship Program
Description: This program supports the development of early career scientists by funding junior postdoctoral fellows doing research of high scientific merit and relevance to ALS.
Funding: Up to $150,000 over 2 years
LOI Deadline (CLOSED): November 21, 2023, 5 p.m. US ET
Full Proposal Deadline (by invitation only): February 13, 2024, 5 p.m. US ET
The Lawrence and Isabel Barnett Drug Development Program
Description: This program supports the preclinical development of new or repurposed treatments for ALS.
Funding: Up to $500,000 over 2 years
LOI Deadline (CLOSED): December 18, 2023, 5 p.m. US ET
Full Proposal Deadline (by invitation only): March 7, 2024, 5 p.m. US ET
Clinical Trial Awards Program
Description: This program supports early- to mid-stage (phase 1 or 2a) interventional clinical trials of novel or repositioned therapeutics for ALS.
Funding: Up to $1,000,000 over 2–3 years
LOI Deadline (CLOSED): January 25, 2024, 5 p.m. US ET
Full Proposal Deadline (by invitation only): April 12, 2024, 5 p.m. US ET
Learn About All Our Awards and Programs
Additional Funding Opportunities
Efficient and Innovative Natural History Studies Addressing Unmet Needs
in Rare Diseases (R01)
Funding Organization: U.S. Food and Drug Administration
Description: This program supports efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs.
Funding: Up to $400,000 per year for 4 years (prospective) or $150,000 per year for 2 years (retrospective or survey)
Deadline: February 13, 2024
ALS Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Funding Organization: National Institute of Neurological Disorders and Stroke (NINDS)
Description: This funding opportunity supports research utilizing data from expanded access studies for ALS using investigational drugs or biological products. Applicants must be clinical trial sites that are participating in a phase 3/efficacy clinical trial supported by a small business concern.
Funding: Up to $40,000,000 has been allocated to fund 2–5 new awards (contingent upon NIH appropriations); maximum project period is 4 years
Deadline: February 22, 2024
Breakthrough Research and Innovation in Drug Development Grants
Funding Organization: Critical Path Institute’s Translational Therapeutics Accelerator
Description: These awards are designed to support academic researchers in traversing the drug development valley of death by funding and defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.
Funding: There are three funding levels. Stage 1: up to $250,000 for 1 year (total cost). Stage 2: up to $500,000 for 1 year (total cost). Stage 3: up to $1,000,000 for 1 year (total cost).
Deadline: March 31, 2024
Natural History, Clinical Outcome Assessment and Biomarker Studies of Rare Neurodegenerative Diseases (U01 Clinical Trials Optional)
Funding Organization: U.S. Food and Drug Administration
Description: This funding opportunity is intended to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults.
Funding: Application budgets are not limited but should reflect the actual needs of the proposed project, including both direct and indirect costs for up to 4 years of support.
Deadline: May 6, 2024
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)
Funding Organization: U.S. Food and Drug Administration
Description: This program funds clinical trials evaluating the efficacy and/or safety of existing products in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions, such as ALS.
Funding: Up to $650,000 per year for 4 years
Open Date: August 23, 2024
Want to add your funding opportunity to this list? Contact us at ResearchGrants@als.org.
